key: cord-0944713-tteamwar
authors: Savarino, Edoardo; Lorenzon, Greta; Ghisa, Matteo; Laserra, Giorgio; Barberio, Brigida; Sc, Daria Maniero; Savarino, Vincenzo; Zingone, Fabiana
title: Lack of Complications in Patients with Eosinophilic Gastrointestinal Diseases During SARS-CoV-2 Outbreak
date: 2020-06-29
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.06.041
sha: 571d64b1243325c57494f0be1a87487b2d76c7a4
doc_id: 944713
cord_uid: tteamwar

nan

Edoardo Savarino MD, PhD 1 , Greta Lorenzon RN 1 , Matteo Ghisa MD 1 , Giorgio Laserra MD 1 events associated with their long-term administration [1, 2] . 55

The severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) responsible for 56

Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020, with over 57 1,250,000 cases and more than 70,000 fatalities reported worldwide as of 6 April 2020. After the 58 outbreak in China, Northern Italy quickly became one of the areas with the highest incidence of 59 new cases. In particular, mortality appears to be highly influenced by age and concomitant presence 60 of chronic diseases. Currently, no data are available on the potential viral effects in patients with 61

EGIDs. Moreover, it is unknown whether their therapies, including both steroids and PPIs, may 62 represent a risk factor for the development of more severe infectious disease or complications [3, 4] . 63

In this prospective, observational, single centre case-controlled study, we investigated 64 whether patients with EGIDs had an increased risk of beaing infected by COVID-19. Between 18 65

March and 6 April 2020, we contacted by e-mail or phone all the EGID patients longitudinally 66

followed-up at the University Hospital of Padua and living in the Veneto Region, who had 67 previously provided written informed consent to be included in our EGID registry (CESC 68 4204/AO/17). For comparison, a group of patients with uncomplicated Celiac Disease (CeD) 69 diagnosed according to international criteria and, routinely followed-up at our center and included 70 in our CeD registry (CESC 4680/AO/19), were asked to complete the same web-based survey. 71

Patients were asked to complete an ad hoc web-based COVID-19 survey (Table E1) with questions 72 relating to demographics, clinical features, type of disease, ongoing therapy, co-morbidities, and 73 information regarding COVID-19 infection.

Out of 145 patients with EGIDs contacted, 130 questionnaires were returned, with a mean 75 age of 37 years and including 28 females, as described in Table 1 . The control group was composed 76 of 135 uncomplicated CeD patients with a mean age 40.9 and which included 102 females.They 77 were interviewed after following a gluten-free diet for an average of 6.6 years (range = 1-36). There 78 were no differences in terms of age (P = 0.256), but the two populations differed in terms of sex (P 79 < 0.0001) and PPI use (P < 0.0001). 80

During the study period, all EGID patients were recommended to continue their treatment 81 regimens (see Table 2 ). Moreover, they declared to have followed the preventive measures 82 Chronic conditions, such as diabetes, cardiovascular diseases, and inflammatory bowel 98 diseases have been associated with increased morbidity and mortality due to COVID-19 infection 99 (5, 6) . By contrast, during the peak phase of the SARS-CoV-2 outbreak in Northern Italy, no cases of COVID-19 infection were reported in our EGID cohort of 135 subjects. Moreover, 15 patients 101 experienced flu-like symptoms, but no complications or development of severe acute respiratory 102 syndrome were seen in them. To note, a similar infection rate and symptom reporting were recorded 103 in our control group of CeD patients. A potential explanation of these discrepancies is that all our 104 EGID patients were in remission at the time of the COVID-19 peak phase and only a minority of 105 our EGID patients were taking corticosteroids or biologics. In addition, the average age of our 106 cohort was relatively low. Therefore, we cannot exclude the possibility that some of our patients 107 were indeed infected by COVID-19, but presented poor or no symptoms. 108

As previously mentioned, at present, there are no data regarding Coronaviridiae infection in 109 EGID patients, especially in those who are taking chronic therapies for their conditions, such as 110 corticosteroids and biologics, which in some cases have been associated to a potential increased risk 111 of infection, including flu (4, 7) . Only a minority of our patients were treated with systemic steroids 112 or biologic drugs. However, we did not observe any influence of these treatments on COVID-19 113 infection and disease outcomes. Moreover, it is relevant to emphasize that recent uncontrolled 114 observations suggest that immunomodulation could even be helpful in a subgroup of severe 115 COVID-19 with hyper-inflammatory features (8) . 116

infections, although the magnitude of this association varies considerably considering the available 118 literature (3). Furthermore, a possible association between PPI use and pneumonia has been 119 hypothesized, due to the potential ascending bacterial colonization from the gut as the effect of the 120 high intragastric pH induced by PPIs. This is relevant since recent studies have observed that in 121 more than 20% of SARS-CoV-2 patients, viral RNA remains positive in feces even after negative 122

conversion of viral RNA in the respiratory tract, thus indicating that gastrointestinal viral infection 123 represents a potential transmission route for the virus (9) . Nevertheless, despite the remarkable 124 intake of acid suppressant drugs by our EGID patients (67.7%), we did not observe confirmed cases 125 of COVID-19 infection in them. 126

In conclusion, despite the limited sample size of our cohort, particularly considering patients 127 with EGE and EC, and the lack of objective assessment of COVID-19, our data suggest that 128 patients with EGIDs do not appear to have an increased risk of morbidity and mortality for SARS-129

CoV-2. Moreover, they can be reassured to safely continue their treatments. These preliminary 

Eosinophilic Gastrointestinal Disorders

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for 138 diagnosis and management in children and adults

Are proton pump inhibitors really so dangerous? Dig 141

Common Infections in Patients Prescribed Systemic 143

Glucocorticoids in Primary Care: A Population-Based Cohort Study

Baseline 146 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to

Outcomes 150 of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Opportunistic infections with anti-tumor necrosis factor-153 alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

UK. COVID-19: consider cytokine storm syndromes and 157 immunosuppression

Evidence for gastrointestinal infection of 1. Please, indicate your date of birth (dd/mm/yyyy), age, sex (male/female), height (cm) and weight (kg)

Are you smoking? Yes/No

Are you affected by eosinophilic esophagitis (Yes/No), eosinophilic gastroenteritis (Yes/No) or eosinophilic colitis (Yes/No)? When the diagnosis was achieved

Are you affected by other allergic comorbidities: rhinitis (Yes/No), conjunctivitis (Yes/No), asthma (Yes/No), atopic dermatitis (Yes/No), others (please

hypertension (Yes/No), hypercholesterolemia (Yes/No), previous surgery (Yes/No), previous neoplasia (Yes/No), ulcerative colitis (Yes/No), Crohn's disease (Yes/No), autoimmune thyroiditis (Yes/No)

Yes/No), gluten free diet (Yes/No), topical steroids such as budesonide spray (Yes/No) or fluticasone spray (Yes/No), systemic steroids such as prednisone (Yes/No) or oral budesonide (Yes/No), biologics such as Vedolizumab (Yes/No) or Omalizumab (Yes/No)

Are you continuing to take the prescribed therapies for your eosinophilic disorder

Are you experiencing symptoms potentially related to your eosinophilic condition? (Yes/No) If yes

Did you undergo seasonal flu vaccination

Have you been diagnosed with COVID 19 infection (i.e. naso-pharyngeal swab)? (Yes/No)

Have you been in contact with someone (friends or family members) diagnosed with COVID 19 (i.e. naso-pharyngeal swab

Did you experience flu-like symptoms (for instance malaise, cough, myalgia, arthralgia, fever, dyspnea) suspected for COVID-19 infection

Did someone in contact with you experience flu-like symptoms (for instance malaise, cough, myalgia, arthralgia, fever, dyspnea) suspected for COVID-19 infection